| Literature DB >> 30084159 |
Jason R Vickress1, Jerry Battista1,2,3, Rob Barnett1,2,3, Slav Yartsev1,2,3.
Abstract
BACKGROUND: Head and neck cancers are commonly treated with radiation therapy, but due to possible volume changes, plan adaptation may be required during the course of treatment. Currently, plan adaptations consume significant clinical resources. Existing methods to evaluate the need for plan adaptation requires deformable image registration (DIR) to a new CT simulation or daily cone beam CT (CBCT) images and the recalculation of the dose distribution. In this study, we explore a tool to assist the decision for plan adaptation using a CBCT without re-computation of dose, allowing for rapid online assessment.Entities:
Keywords: adaptive radiotherapy; cone beam CT; deformable image registration; head and neck cancer; image-guided radiotherapy; radiotherapy
Mesh:
Year: 2018 PMID: 30084159 PMCID: PMC6123138 DOI: 10.1002/acm2.12432
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1Illustration of the CBCT method for the evaluation of the need for plan adaptation using the DIR of planning CT to daily CBCT study and the planned dose distribution. DIR—deformable image registration, RR—rigid registration.
Figure 2Schema describing the daily dose estimation using DIR from the planning CT to either the daily CBCT or re CT study (ReCT). Two different dose distributions computed on the PCT or ReCT are transferred to the moving image using a 6 degree of freedom rigid registration. The gold standard method is highlighted in yellow using the ReCT and recomputed dose. Day X is when ReCT was ordered due to observed significant anatomical changes.
Relative voxel‐wise dose difference from gold standard (ReCTR) (RD) for ipsilateral and contralateral parotids and spinal cord, averaged over 18 patients. Standard deviation is displayed in brackets
| Secondary image and dose distribution | Ipsilateral parotid | Contralateral parotid | Spinal cord |
|---|---|---|---|
| ReCTP | 8% (5.7%) | 7.9% (5%) | 3.8% (1.6%) |
| CBCTP | 12.7% (9.5%) | 13.5% (7.8%) | 5.7% (2.4%) |
| CBCTR | 7.5% (4%) | 7.7% (4.5%) | 4% (2%) |
Figure 3Predicted mean dose using a) CBCT and b) CBCT methods compared to ReCT (gold standard) for 15 parotid glands. Clinical threshold of 26 Gy is shown by solid lines. ReCT is the DIR to ReCT using the recalculated dose. CBCT is the DIR to daily CBCT using the planned dose. CBCT is the DIR to daily CBCT using the recalculated dose.
Figure 4The difference between predicted D95 and the prescribed dose for the PTV for using a) CBCT and b) CBCT methods compared to ReCT (gold standard). Values are presented as the difference from the prescribed dose. Dashed line represents conservative criteria (within 1 Gy of threshold). ReCT is the DIR to ReCT using the recalculated dose. CBCT is the DIR to daily CBCT using the planned dose. CBCT is the DIR to daily CBCT using the recalculated dose.